Premium
O1‐03‐04: Paris: A new comprehensive language tool for the diagnosis and categorization of primary progressive aphasia
Author(s) -
Saade Yasmina Michel,
Ferrieux Sophie,
Arbizu Céline,
Saratxaga Adriana Amaya,
Hermann Bertrand,
Henry-Amar François,
Nogues Marie,
Azuar Carole,
Dubois Bruno,
Epelbaum Stéphane,
Teichmann Marc
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.042
Subject(s) - primary progressive aphasia , aphasia , boston naming test , categorization , sentence , audiology , medicine , apraxia , test (biology) , psychology , disease , dementia , natural language processing , cognitive psychology , computer science , artificial intelligence , pathology , frontotemporal dementia , biology , paleontology
otherwise undetectable cognitive deficits in preclinical AD. We aimed to compare the effects of low-dose (0.20mg s.c.) scopolamine on cognition between Ab+ and AbCN older adults using the Groton Maze Learning Task (GMLT). Methods: Cognitively normal (CN) older adults (n1⁄463), with a family history of AD and subjective memory complaints, completed the GMLT predose, and then received low-dose scopolamine (0.20 mg) subcutaneously. Participants were re-assessed 1-, 3-, 5-, 7-, and 8hours post-dose. All participants underwent positron emission tomography (PET) neuroimaging for Ab using F-florbetapir within 6 weeks of their baseline visit. Fifteen CN older adults were classified as Ab+ and 48 were classified as Ab-. Results: At 5-hours post-dose, the Ab+ group performed significantly worse than the Abgroup on all measures of learning efficiency and working memory/executive function (Cohen’s d1⁄41.13-1.56). When participants were classified as having an abnormal response to scopolamine (based on change score at 5-hours post-dose greater than zero), 100% were correctly classified as Ab+ and 67% as Ab-. Conclusions: Depletion of cortical cholinergic neurotransmission is a characteristic feature of AD, and may be mechanistically related to Ab-related disruption to the cholinergic system. In individuals at risk for AD (e.g., individuals with MCI), or who later progress to AD, neurodegenerative changes are evident within the basal forebrain cholinergic system and the nucleus basalis of Meynert (NbM). Results of this study suggest that diminished cholinergic tone likely also occurs in preclinical AD, and as such, the use of a cholinergic stress test to perturb an already compromised neurotransmitter system may be an effective way of identifying CN older adults with substantial neocortical beta-amyloid aggregation and who are in the preclinical stage of AD.